insulin drugs glp 1 receptor agonist market GLP-1 Agonists Weight Loss Report, 2025-2030 GLP-1 Receptor Agonist Market Size,

Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity

These actions improve glycemic control and support weight loss

Over time, some patients may need to pause or stop therapy due to side effects, plateaus, or changing goals

Connect with certified providers on Meto for personalized support and results

The global obesity treatment market is expanding at unprecedented speed, with sales of weight-loss medications forecast to rise dramatically over the next decade.